Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Death/hospitalization 51% Improvement Relative Risk c19early.org/m Evans et al. Molnupiravir for COVID-19 EARLY TREATMENT Is early treatment with molnupiravir beneficial for COVID-19? Retrospective 5,332 patients in the United Kingdom (Dec 2021 - Apr 2022) Lower death/hosp. with molnupiravir (p=0.0078) Evans et al., J. Infection, doi:10.1016/j.jinf.2023.02.012 Favors molnupiravir Favors control
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study
Evans et al., Journal of Infection, doi:10.1016/j.jinf.2023.02.012
Evans et al., Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital.., Journal of Infection, doi:10.1016/j.jinf.2023.02.012
Jan 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective high risk outpatients in the UK, showing lower hospitalization/death with molnupiravir treatment. Residual confounding is likely with adjustments having no detail on specific comorbidities.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom]. See [Fountain-Jones, Sanderson, twitter.com] for analysis of variants potentially created by molnupiravir.
risk of death/hospitalization, 51.0% lower, HR 0.49, p = 0.008, treatment 359, control 4,973, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Evans et al., 25 Jan 2023, retrospective, United Kingdom, peer-reviewed, 11 authors, study period 16 December, 2021 - 22 April, 2022.
Contact: andrew.evans@gov.wales, cathy.qi@swansea.ac.uk, j.o.adebayo@swansea.ac.uk, underwoodj7@cardiff.ac.uk, coulsonjm@cardiff.ac.uk, r.bailey@swansea.ac.uk, gareth.john@wales.nhs.uk, edwardsag@cardiff.ac.uk, coopera8@cardiff.ac.uk, r.a.lyons@swansea.ac.uk, a.akbari@swansea.ac.uk.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2023.01.24.23284916; this version posted January 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study Authors Andrew Evans, Chief Pharmaceutical Officer, Health and Social Services Group, Welsh Government, Cathays Park, Cardiff CF10 3NQ (corresponding author) Andrew.Evans@gov.wales Cathy Qi, Statistician and Research Officer, Population Data Science, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park Swansea SA2 8PP Cathy.Qi@swansea.ac.uk Lolu Adebayo, Research Officer, Population Data Science, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park Swansea SA2 8PP J.O.Adebayo@swansea.ac.uk Jonathan Underwood, Clinical Academic Research Partnership Fellow, School of Medicine, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN underwoodj7@cardiff.ac.uk James Coulson, Clinical Reader, School of Medicine, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN Coulsonjm@cardiff.ac.uk Rowena Bailey, Senior Research Officer, Population Data Science, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park Swansea SA2 8PP r.bailey@swansea.ac.uk Gareth John, Information Systems Development and Design Lead, Information Services Directorate, Digital Health and Care Wales, Tŷ Glan-yr-Afon, 21 Cowbridge Road East, Cardiff CF11 9AD Gareth.John@wales.nhs.uk Adrian Edwards, Professor of General Practice, Division of Population Medicine, Director, PRIME Centre Wales and Wales COVID-19 Evidence Centre. Division of Population Medicine, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, CF14 4YS Edwardsag@cardiff.ac.uk Alison Cooper, Associate Academic Fellow, Wales Covid-19 Evidence Centre. Division of Population Medicine, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, CF14 4YS Coopera8@cardiff.ac.uk Ronan A Lyons, Clinical Professor of Public Health, Population Data Science, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park Swansea SA2 8PP r.a.lyons@swansea.ac.uk Ashley Akbari, Associate Professor Population Data Science Research, Population Data Science, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park Swansea SA2 8PP a.akbari@swansea.ac.uk NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2023.01.24.23284916; this version posted January 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Abstract Objective To compare the effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab with..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit